Salix announces FDA approval of Xifaxan® 550 mg for treatment of IBS-D
Valeant announced its subsidiary, Salix has received approval from the FDA for Xifaxan® 550 mg for treatment of IBS-D in adults. The FDA approval of Xifaxan 550 mg is based on data from three phase 3 studies. Xifaxan 550 mg was studied in over 3,000 patients and demonstrated efficacy and safety. May 27, 2015